Ascletis Pharma Inc (1672)

Currency in HKD
16.47
-0.04(-0.24%)
Closed·
1672 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
16.2917.15
52 wk Range
5.3019.86
Key Statistics
Bid/Ask
16.47 / 16.47
Prev. Close
16.51
Open
16.52
Day's Range
16.29-17.15
52 wk Range
5.3-19.86
Volume
1.12M
Average Volume (3m)
2.71M
1-Year Change
147.1557%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
1672 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
22.31
Upside
+35.45%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Ascletis Pharma Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 22.31
(+35.45% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Goldman Sachs
Hold15.71-4.61%13.76MaintainApr 03, 2026
Goldman Sachs
Hold12.84-22.04%14.75MaintainOct 27, 2025
Citi
Buy32.00+94.29%20.00MaintainAug 25, 2025
Goldman Sachs
Hold14.75-10.44%9.41MaintainAug 21, 2025
Goldman Sachs
Hold9.41-42.87%4.92MaintainJul 09, 2025

Earnings

Latest Release
Mar 31, 2026
EPS / Forecast
-0.28 / --
Revenue / Forecast
947K / --
EPS Revisions
Last 90 days

1672 Income Statement

Compare 1672 to Peers and Sector

Metrics to compare
1672
Peers
Sector
Relationship
P/E Ratio
−42.3x−16.6x−0.5x
PEG Ratio
1.830.090.00
Price/Book
7.9x5.1x2.6x
Price / LTM Sales
7,509.2x15.4x3.2x
Upside (Analyst Target)
14.9%41.4%48.8%
Fair Value Upside
Unlock0.3%6.9%Unlock

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.

Employees
208
Market
Hong Kong

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
43.99M4.15%726.28M
Other Institutional Investors
270.91M25.53%4.47B
Public Companies & Retail Investors
746.23M70.32%12.32B
Total
1.06B100.00%17.52B

FAQ

What Is the Ascletis Pharma (1672) Stock Price Today?

The Ascletis Pharma stock price today is 16.47 HKD.

What Stock Exchange Does Ascletis Pharma Trade On?

Ascletis Pharma is listed and trades on the Hong Kong Stock Exchange.

What Is the Stock Symbol for Ascletis Pharma?

The stock symbol for Ascletis Pharma is "1672."

What Is the Ascletis Pharma Market Cap?

As of today, Ascletis Pharma market cap is 17.48B HKD.

What Is Ascletis Pharma's Earnings Per Share (TTM)?

The Ascletis Pharma EPS (TTM) is -0.37.

From a Technical Analysis Perspective, Is 1672 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Ascletis Pharma Stock Split?

Ascletis Pharma has split 0 times.

How Many Employees Does Ascletis Pharma Have?

Ascletis Pharma has 208 employees.

What is the current trading status of Ascletis Pharma (1672)?

As of May 01, 2026, Ascletis Pharma (1672) is trading at a price of 16.47 HKD, with a previous close of 16.51 HKD. The stock has fluctuated within a day range of 16.29 HKD to 17.15 HKD, while its 52-week range spans from 5.30 HKD to 19.86 HKD.

What Is Ascletis Pharma (1672) Price Target According to Analysts?

The average 12-month price target for Ascletis Pharma is 22.31 HKD, with a high estimate of 32.17037377 HKD and a low estimate of 15.84613621 HKD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +35.45% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.